National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2017 (No. 8) (PB 67 of 2017) (Cth)

PB 67 of 2017

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2017 (No. 8)

National Health Act 1953

I, JULIANNE QUAINE, Assistant Secretary, Pharmacy and Insurance Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated 29 August 2017

JULIANNE QUAINE

Assistant Secretary

Pharmacy and Insurance Branch

Technology Assessment and Access Division

Department of Health

1  Name of Instrument

(1)   This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2017 (No. 8).

(2)        This Instrument may also be cited as PB 67 of 2017.

2  Commencement

This Instrument commences on 1 September 2017.

3  Amendment of PB 79 of 2011

This Instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

4  Schedules

The National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011) is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1     Amendments

1. Schedule 1, Part 1, entry for Rituximab in each of the forms: Solution for I.V. infusion 100 mg in 10 mL; and Solution for I.V. infusion 500 mg in 50 mL

omit from the column headed “Circumstances”:            C4706

insert in numerical order:      C7040

1. Schedule 1, Part 2 entry for Bevacizumab

omit from the column headed “Purposes”:    C4968

substitute:  P4968

1. Schedule 1, Part 2 entry for Rituximab

(a)      omit:

P4706 1100 5

(b)      after the entry:

P6161 800 11

insert:

P7040 1100 5

1. Schedule 2, entry for Ondansetron in each of the forms: I.V. injection 4 mg (as hydrochloride dihydrate) in 2 mL; and I.V. injection 8 mg (as hydrochloride dihydrate) in 4 mL

omit:

Ondansetron‑Claris AE EMP C5749 1 0

1. Schedule 4, entry for Rituximab

(a)      omit:

C4706 P4706 Chronic lymphocytic leukaemia (CLL)
The condition must be CD20 positive chronic lymphocytic leukaemia (CLL); AND
The treatment must be in combination with chemotherapy. Compliance with Authority Required procedures ‑ Streamlined Authority Code 4706

(b)      insert in numerical order after existing text:

C7040 P7040 Chronic lymphocytic leukaemia (CLL) The condition must be CD20 positive; AND The treatment must be in combination with chemotherapy or idelalisib. Compliance with Authority Required procedures - Streamlined Authority Code 7040